source
- FDA’s 505(b)(2) pathway offers faster, cheaper drug development and commercial gainsThe FDA’s 505(b)(2) regulatory route lets drug sponsors build on existing safety and efficacy data while proposing meaningful changes to a known product. By leveraging prior findings, companies can…
- Novo Nordisk sues Eli Lilly, alleging deceptive ads that misrepresent GLP-1 drug efficacyNovo Nordisk filed a lawsuit in federal court in New Jersey accusing Eli Lilly of running a deceptive advertising campaign. The complaint says Lilly’s ads compare the highest doses of its weight‑l…